PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
By Holly Campbell | March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt patients’ ability...
Read More
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
By Nicole Longo | August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....
Read More
Five key facts about the market for insulins
By Holly Campbell | April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...
Read More
The PBM story you haven’t heard: Hidden fees quadrupled in two years
By Robert Zirkelbach | March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...
Read More
OptumRX: Sharing rebates with patients is “worth it”
By Holly Campbell | March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...
Read More
Event tomorrow: Making the biopharmaceutical supply chain work for patients
By Katie Koziara | May 2, 2018
In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...
Read More
Advance price notification: A transparency measure that fails patients
By Saumil Pandya and Emily Donaldson | March 29, 2018
Most transparency reforms aim to correct perceived misaligned incentives in the biopharmaceutical marketplace. However, many efforts to mandate information flow in the private market have serious...
Read More
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
By Holly Campbell | March 27, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could...
Read More
ICYMI – Two PBM reports show dramatic slowdown in medicine spending growth
By Holly Campbell | March 2, 2018
Newly released pharmacy benefit manager (PBM) data show medicine spending is growing at the slowest rate in years. After accounting for discounts and rebates negotiated with biopharmaceutical...
Read More
Copay coupons can help ease patients’ out-of-pocket costs
By Holly Campbell | February 16, 2018
Each year, middlemen, like pharmacy benefit managers (PBMs) and insurers, shift more of the costs of health care to patients. Ensuring patients have affordable access to their medicines is the top...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
